AbbVie
259,90 $Variazione rispetto alla chiusura precedente: −0,65%Variazione assoluta: −1,69 $
Ultime notizie
Titoli nella lingua originale della fonte.
- AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? (si apre in una nuova scheda)
- AbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO Approval (si apre in una nuova scheda)
- AbbVie to Host Third-Quarter 2026 Earnings Conference Call (si apre in una nuova scheda)
- 5 Solid Dividend Stocks to Buy Now (si apre in una nuova scheda)
- AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It (si apre in una nuova scheda)
- 5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test) (si apre in una nuova scheda)
- ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? (si apre in una nuova scheda)
- Was The Run In JNJ Stock Hiding In Plain Sight? (si apre in una nuova scheda)
- AbbVie Stock: Buy, Sell, or Hold in October? (si apre in una nuova scheda)
- Are You Overpaying For Pfizer Stock Versus Its Rivals? (si apre in una nuova scheda)
- What Does AbbVie (ABBV) Need To Prove After Its Eczema Drug And AI Update? (si apre in una nuova scheda)
- What Is Merck Stock's Biggest Opportunity? (si apre in una nuova scheda)
- 1 Profitable Stock to Keep an Eye On and 2 Facing Challenges (si apre in una nuova scheda)
- BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength (si apre in una nuova scheda)
- AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis (si apre in una nuova scheda)
- AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 (si apre in una nuova scheda)
- AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know (si apre in una nuova scheda)
- Defensive Dividends: 3 Companies Investors Can Rely On (si apre in una nuova scheda)
- Is Eli Lilly Stock a Good Fit For Your Portfolio Risk? (si apre in una nuova scheda)
- Final Trade: Abbvie, Advanced Micro, SpaceX, Eaton Corp. (si apre in una nuova scheda)
- Amazon, Walmart Surplus Auctioneer Climbs Toward A Breakout; Stock Up 45% (si apre in una nuova scheda)
- Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree? (si apre in una nuova scheda)
- AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval (si apre in una nuova scheda)
- AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says (si apre in una nuova scheda)
- AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo (si apre in una nuova scheda)
- ESPN unveils 2026 MLB Postseason coverage plans beginning with Wild Card Series presented by AbbVie (si apre in una nuova scheda)
- Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium (si apre in una nuova scheda)
- AbbVie Teams Up With Valkai to Use AI in Clinical Development (si apre in una nuova scheda)
- AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development (si apre in una nuova scheda)
- The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell (si apre in una nuova scheda)